scholarly journals The North Jutland County Diabetic Retinopathy Study (NCDRS) 2. Non-ophthalmic parameters and clinically significant macular oedema

2007 ◽  
Vol 91 (12) ◽  
pp. 1593-1595 ◽  
Author(s):  
L L Knudsen ◽  
H-H Lervang ◽  
S Lundbye-Christensen ◽  
A Gorst-Rasmussen
Keyword(s):  
Diabetic Retinopathy ◽  
Macular Oedema ◽  
The North ◽  
Clinically Significant ◽  
Clinically Significant Macular Oedema

scholarly journals Alpha-lipoic acid in non-proliferative diabetic retinopathy treatment

2011 ◽  
Vol 14 (4) ◽  
pp. 82-86 ◽  
Author(s):  
Tatiana Yul'evna Demidova ◽  
Yulia Alexandrovna Trakhtenberg
Keyword(s):  
Diabetic Retinopathy ◽  
Proliferative Diabetic Retinopathy ◽  
Lipoic Acid ◽  
Macular Oedema ◽  
Alpha Lipoic Acid ◽  
Severe Stage ◽  
Clinically Significant ◽  
Clinically Significant Macular Oedema

Aim. The aim of this study is to assess the therapeutic efficacy of alpha-lipoic acid in patients with type 2 diabetes mellitus (DM) and non-proliferativediabetic retinopathy. Materials and methods. 47 patients with mild to moderate non-proliferative diabetic retinopathy were included in this trial. Dynamics of ophthalmologicparameters were assessed by means of stereoscopic photography of ocular fundus. Patients were examined every 6 months in order to registernew cases of clinically significant macular oedema. Results. During 24 months follow-up period, patients treated with 600 mg of alpha-lipoic acid showed stabilization in development of diabetic retinopathy.New cases of macular oedema, as well as transition into a more severe stage of retonopathy were less common in those patients. Vision andcontrast sensation also remained stable in the majority of participants from experimental group.Conclusions. 600 mg of alpha-lipoic acid may be recommended for patients with type 2 DM as part of complex therapy

scholarly journals Subthreshold 577 nm laser photocoagulation vesus conventional 532 nm laser photocoagulation for diabetic macular oedema

2021 ◽  
Vol 3 (3) ◽  
pp. 123-140
Author(s):  
Linda Sui-Lin Ong ◽  
Tajunisah Mohd Iqbal ◽  
Kenneth Choong-Sian Fong
Keyword(s):  
Diode Laser ◽  
Macular Oedema ◽  
Laser Photocoagulation ◽  
Retinal Thickness ◽  
Diabetic Macular Oedema ◽  
Macular Thickness ◽  
Clinically Significant ◽  
Clinically Significant Macular Oedema ◽  
532 Nm

Purpose: To evaluate the visual and anatomic outcomes of the subthreshold micropulse 577 nm yellow diode laser (MYL) and to compare its efficacy with the conventional green 532 nm diode laser (CGL) in Asian eyes with diabetic macular oedema (DME).Study design: Prospective randomized controlled clinical trialMethods: Sixty-seven eyes of 43 patients with clinically significant macular oedema (CSME) were randomized to receive either MYL (n = 37) or CGL (n = 30) at baseline and were followed up for 12 months. Titration in the MYL group was performed with 15% duty cycle, 300 ms duration, and double the threshold power, while the modified Early Treatment of Diabetic Retinopathy Study (mETDRS) protocol was used for the CGL arm with the power titrated to a barely visible burn. Parameters noted included best-corrected visual acuity (BCVA) (logMAR), central subfoveal thickness (CST), macular volume (MV), and average macular thickness (AMT) using optical coherence tomography, and presence of visible laser scars on colour fundus photographs and fundus autofluorescence, at baseline and at 12 months.Results: At 12 months follow-up, BCVA improved by 4.7 and 8.8 letters, respectively, for the MYL and CGL treatment arms (p < 0.05). There was a significant reduction in all retinal thickness parameters (CST, MV, and AMT) when compared to baseline in both laser treatment arms at 12 months. There was no significant difference in either BCVA or retinal thickness parameters between the two treatment arms at 1, 3, 6, 9, or 12-month follow-up. Laser scars were observed in 26.7% of patients in the MYL group compared to 75% of patients in the CGL group (p = 0.029).Conclusions: MYL is an effective, safe, and patient-friendly treatment option for clinically significant macular oedema, with improvement in BCVA, reduction in macular thickness, and less scarring after treatment at 12 months.

Vitrectomy with internal limiting membrane removal for clinically significant macular oedema

2004 ◽  
Vol 242 (5) ◽  
pp. 402-408 ◽  
Author(s):  
Ferenc Kuhn ◽  
Gyöngyi Kiss ◽  
Viktória Mester ◽  
Zsuzsanna Szijártó ◽  
Bálint Kovács
Keyword(s):  
Macular Oedema ◽  
Internal Limiting Membrane ◽  
Clinically Significant ◽  
Clinically Significant Macular Oedema

One-year real-life results on effect of intravitreal aflibercept in patients with diabetic macular oedema switched from ranibizumab

2020 ◽  
pp. 112067212092727
Author(s):  
Marko Lukic ◽  
Gwyn Williams ◽  
Zaid Shalchi ◽  
Praveen J Patel ◽  
Philip G Hykin ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Diabetic Retinopathy ◽  
Early Treatment ◽  
Macular Oedema ◽  
Real Life ◽  
Diabetic Macular Oedema ◽  
Foveal Thickness ◽  
Macular Volume ◽  
Central Foveal Thickness ◽  
The Mean

Purpose To assess visual and optical coherence tomography–derived anatomical outcomes of treatment with intravitreal aflibercept (Eylea®) for diabetic macular oedema in patients switched from intravitreal ranibizumab (Lucentis®). Design Retrospective, cohort study. Participants Ninety eyes (of 67 patients) receiving intravitreal anti–vascular endothelial growth factor therapy were included. Methods This is a retrospective, real-life, cohort study. Each patient had visual acuity measurements and optical coherence tomography scans performed at baseline and 12 months after the first injection of aflibercept was given. Main Outcome Measures We measured visual acuities in Early Treatment Diabetic Retinopathy Study letters, central foveal thickness and macular volume at baseline and at 12 months after the first aflibercept injection was given. Results Ninety switched eyes were included in this study. The mean (standard deviation) visual acuity was 63 (15.78) Early Treatment Diabetic Retinopathy Study letters. At baseline, the mean (standard deviation) central foveal thickness was 417.7 (158.4) μm and the mean macular volume was 9.96 (2.44) mm3. Mean change in visual acuity was +4 Early Treatment Diabetic Retinopathy Study letters (p = 0.0053). The mean change in macular volume was −1.53 mm 3 in SW group (p = 0.21), while the change in central foveal thickness was −136.8 μm (p = 0.69). Conclusion There was a significant improvement in visual acuity and in anatomical outcomes in the switched group at 12 months after commencing treatment with aflibercept for diabetic macular oedema.

Sign in / Sign up

Export Citation Format

Share Document